Friday 6 November 2026 Export VCEL’s income statement to Excel — free account

Vericel Corporation

VCEL Healthcare Biotechnology

Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.

Revenue: +26.5%
EPS: +180.0%
Free cash flow: −19.4%

Quarter to September 2026, against a year earlier

Revenue growth 10 yrs

54.47 2.69 +5.20%

Follow VCEL

Alert me

Market cap: $2.7B
P/E: 77.8×
Fwd P/E: 72.9×
Dividend yield: —
F-score: 7/9
Altman Z: 8.21
Beneish M: −2.53
Dividend safety: n/a

Overview

Vericel Corporation (VCEL) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Vericel Corporation (VCEL) trades at a P/B ratio of 6.8×. Over the past ten years it has ranged from 0.0× (March 2017) to 25.2× (May 2018); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VCEL/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Vericel Corporation P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VCEL/metrics/pb-ratio">Vericel Corporation (VCEL) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	5.1×	(44.36%)
FY2024	9.2×	25.05%
FY2023	7.3×	19.26%
FY2022	6.2×	(42.51%)
FY2021	10.7×	3.01%
FY2020	10.4×	50.31%
FY2019	6.9×	1.03%
FY2018	6.8×	(21.55%)
FY2017	8.7×	—
FY2016	0.0×	—

Period	P/B ratio	Change
Sep 2026	5.3×	(12.91%)
Jun 2026	6.1×	33.93%
Mar 2026	4.6×	(10.30%)
Dec 2025	5.1×	3.54%
43 more quarters	Free account

Against its own ten years

Low 0.0× High 25.2×

Ten-year median 7.2×

Current reading's percentile 32

Company	P/B ratio
BHVN Biohaven Ltd. compare	n/m
CLDX Celldex Therapeutics, Inc. compare	3.1×
AUPH Aurinia Pharmaceuticals Inc compare	3.3×
IMNM Immunome, Inc. compare	3.9×
VERA Vera Therapeutics, Inc. compare	5.3×
PHVS Pharvaris N.V. compare	6.4×
ADMA ADMA Biologics Inc compare	6.7×
VCEL Vericel Corporation	6.8×
PVLA Palvella Therapeutics, Inc. compare	10.4×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Vericel Corporation (VCEL) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on VCEL

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on VCEL

Stockrow Weekly